Sales Battle Card: Vicero, Inc. CMO Alert
Vicero’s new CMO is your pipeline trigger. Pitch end-to-end clinical ops to speed first-in-human trials. Add safety analytics to close faster.
Published on
Do not index
Do not index
🚀 Battle Card: Vicero, Inc.
Quick trigger:
👤 Decision Maker in the News
- Han Myint, MD, FACP, Chief Medical Officer · 🔗 LinkedIn
💡 Why It Matters
- New CMO brings 30+ years advancing breakthrough oncology therapies from first-in-human studies through FDA approvals → Source
🎯 Core Pain Point
- Speeding IND-enabling studies for novel bispecific VHH VINCOBODIES
- Mitigating immune-related toxicities in early-stage solid tumor trials
💰 What to Pitch
- Primary: End-to-end clinical operations platform → accelerate first-in-human trials for VCR-036
- Expansion: Safety data analytics suite → minimize immune-related adverse events
🗺️ Quick Context
- HQ: Cambridge, MA
- Employees: ≈ 50
- Rev: ≈ $5 M
- Website: vicerobio.com
🤼 Competitive Intel
Which other vendors you’ll probably face to win Vicero, Inc.’s business.
- Parexel — CRO / Clinical Development
- Unique edge: Global regulatory & trial design expertise
- Evaluated by CMO & VP of Clinical Operations for IND readiness
- IQVIA — CRO / Data & Analytics
- Unique edge: Real-world data insights & massive patient recruitment
- Evaluated by CMO & Dir. of Biomedical Informatics for enrollment speed
- PPD — CRO / Full-service Trials
- Unique edge: Integrated lab services & global site network
- Evaluated by Chief Medical Officer for safety monitoring
- Labcorp — CRO / Safety Monitoring
- Unique edge: Centralized immunogenicity & biomarker labs
- Evaluated by CMO & Head of Quality for toxicity management
✅ Do-Now Checklist
Connect with Han Myint and Vikram Kansra on LinkedIn (links above)
Craft email + DM referencing this Vicero, Inc. sales trigger and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Never miss a Vicero, Inc. sales trigger—get hyper-actionable intel like this daily.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑End-to-end clinical operations platform to accelerate first-in-human oncology trials❑
PROOF_METRIC = ❑30% faster IND submission❑
CTA_STYLE = ❑quick_call❑
TONE = ❑punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Han
COMPANY = Vicero, Inc.
DEPT = Clinical
SIZE = ≈8
BOTTLENECK = IND-enabling study delays
EVENT = new CMO appointment
DETAIL = Dr. Han Myint joining as CMO
PAIN = speeding IND-enabling studies & mitigating immune-related toxicities
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250909324505&div=41152219
SIM_CO = NexImmune
WIN_METRIC = 30% faster trial startup
NEXT_SIZE = ≈20
EMP_EST = ≈50
REV_EST = ≈$5M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈8-person Clinical
Han—noticed your Clinical team is ≈ 8.
That’s when IND-enabling study delays slows growth.
We helped NexImmune fix this with End-to-end clinical operations platform to accelerate first-in-human oncology trials.
Result: 30% faster trial startup.
Quick call?
PS—next bottleneck hits ≈ 20.
DM ≤45 words, TONE:
Saw your post about Dr. Han Myint joining as CMO — speeding IND-enabling studies & mitigating immune-related toxicities.
End-to-end clinical operations platform to accelerate first-in-human oncology trials. 30% faster IND submission.
Quick chat?```